Novo Nordisk’s Wegovy Nabs CHMP Recommendation for Use in Teens

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the Novo Nordisk weight-loss medication Wegovy (semaglutide) for use in adolescents 12 and up. The move comes after a phase 3 trial showed the drug to be effective teens, with almost 3/4ths of participants losing 5% of their body weight.

According to Emily Kimber, “Semaglutide, which is also available under the brand names Ozempic and Rybelsus, suppresses patients’ appetites by mimicking an intestinal hormone called GLP-1, which is released after eating. By making people feel fuller, it should help to reduce overall calorie intake.”

To read more, click here.

(Source: PM Live, April 3^rd, 2023)